DDX53 and neoplasm: Tumor growth was significantly inhibited at all dose levels (Fig. 3A), consistent with previous dose titration experiments showing TransCon TLR7/8 Agonist inhibited CT26 (Additional file 3: Figure S2) and MC38 (Additional file 4: Figure S3) tumor growth in a dose-dependent manner.